Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First or Second Line Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02539225
What this trial is testing

Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 191
Not applicableStudy completedNCT02246725
What this trial is testing

Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.

Who this might be right for
Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer
Lund University Hospital 108
Testing effectiveness (Phase 2)Ended earlyNCT01521143
What this trial is testing

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

Who this might be right for
Epithelial Ovarian Cancer
Prima BioMed Ltd 91
Testing effectiveness (Phase 2)Ended earlyNCT00084487
What this trial is testing

Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

Who this might be right for
Extensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
National Cancer Institute (NCI) 21
Not applicableStudy completedNCT03896984
What this trial is testing

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer 346
Early research (Phase 1)Active Not RecruitingNCT06542731
What this trial is testing

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Ono Pharmaceutical Co., Ltd. 42
Large-scale testing (Phase 3)Study completedNCT02898077
What this trial is testing

Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Eli Lilly and Company 440
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07780578
What this trial is testing

The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Fudan University 34
Large-scale testing (Phase 3)Study completedNCT02490488
What this trial is testing

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
AB Science 248
Testing effectiveness (Phase 2)Study completedNCT01282463
What this trial is testing

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Who this might be right for
Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of Ureter+1 more
Eli Lilly and Company 148
Testing effectiveness (Phase 2)Ended earlyNCT04363801
What this trial is testing

DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Who this might be right for
Gastric CancerGastric AdenocarcinomaGastroEsophageal Cancer
Leap Therapeutics, Inc. 247
Testing effectiveness (Phase 2)Ended earlyNCT00852332
What this trial is testing

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
Centre Jean Perrin 42
Not applicableStudy completedNCT05658601
What this trial is testing

Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb 104
Testing effectiveness (Phase 2)Study completedNCT01788982
What this trial is testing

Nintedanib(BIBF1120) in Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer (MTC)Differentiated Thyroid Cancer (DTC)
European Organisation for Research and Treatment of Cancer - EORTC 100
Testing effectiveness (Phase 2)UnknownNCT04755868
What this trial is testing

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Yonsei University 206
Testing effectiveness (Phase 2)Ended earlyNCT00727207
What this trial is testing

Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Who this might be right for
Lymphoma
Technical University of Munich 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592612
What this trial is testing

Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

Who this might be right for
Hepatocellular CarcinomaOligoprogression
Sun Yat-sen University 70
Testing effectiveness (Phase 2)Ended earlyNCT02423902
What this trial is testing

Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Alaunos Therapeutics 9
Early research (Phase 1)Study completedNCT02387138
What this trial is testing

A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan

Who this might be right for
Digestive Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 24
Early research (Phase 1)Ended earlyNCT01238029
What this trial is testing

Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 PositiveFirst or Second Line Therapy+1 more
Sponsor GmbH 12
Next Page